标题
SGLT2i: beyond the glucose-lowering effect
作者
关键词
-
出版物
Cardiovascular Diabetology
Volume 19, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-06-27
DOI
10.1186/s12933-020-01071-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Metformin and cardiorenal outcomes in diabetes: A reappraisal
- (2020) John R. Petrie et al. DIABETES OBESITY & METABOLISM
- Efficacy and tolerability of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A systematic review and network meta‐analysis
- (2020) Humaira Hussein et al. DIABETES OBESITY & METABOLISM
- Can the Cardiovascular Risk Reductions Observed with Empagliflozin in the EMPA‐REG OUTCOME Trial be Explained by Concomitant Changes Seen in Conventional Cardiovascular Risk Factor Levels?
- (2020) Ruth L. Coleman et al. DIABETES OBESITY & METABOLISM
- Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
- (2020) Thomas A. Zelniker et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
- (2020) Kieran F Docherty et al. EUROPEAN HEART JOURNAL
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease
- (2020) Kazuomi Kario et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes
- (2020) Yinqiu Yang et al. Frontiers in Endocrinology
- Reduction in the incidence of myocardial infarction with sodium–glucose linked cotransporter-2 inhibitors: evident and plausible
- (2019) Richard E. Gilbert et al. Cardiovascular Diabetology
- Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
- (2019) Radica Z. Alicic et al. DIABETES
- Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
- (2019) Yangli Ye et al. Frontiers in Pharmacology
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
- (2019) Donna K. Arnett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
- (2019) Chiara Maria Assunta Cefalo et al. Cardiovascular Diabetology
- SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
- (2019) Chenguang Li et al. Cardiovascular Diabetology
- Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials
- (2019) Dario Giugliano et al. DIABETES OBESITY & METABOLISM
- A safety update on sodium glucose co‐transporter 2 inhibitors
- (2019) David Fitchett DIABETES OBESITY & METABOLISM
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
- (2019) Jaime A Davidson POSTGRADUATE MEDICINE
- Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
- (2019) Akira Sezai et al. Cardiovascular Diabetology
- SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
- (2019) Carlo Garofalo et al. Medicina-Lithuania
- Diabetes Technology: Review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes
- (2019) James J. Chamberlain et al. ANNALS OF INTERNAL MEDICINE
- Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
- (2019) Benedetta Maria Bonora et al. Cardiovascular Diabetology
- Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)
- (2019) Sho Kinguchi et al. Cardiovascular Diabetology
- Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents
- (2019) Boris Fishman et al. Cardiovascular Diabetology
- Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer antihyperglycaemic drug matters?
- (2019) Dario Giugliano et al. DIABETES OBESITY & METABOLISM
- Effects of sodium‐glucose cotransporter‐2 inhibitors on the cardiovascular and renal complications of type 2 diabetes
- (2019) Robert J. Chilton DIABETES OBESITY & METABOLISM
- Intrauterine programming of obesity and type 2 diabetes
- (2019) Denise S. Fernandez-Twinn et al. DIABETOLOGIA
- Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage
- (2019) Habib Yaribeygi et al. LIFE SCIENCES
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Review of Diabetes Prediction Equations in African Descent Populations
- (2019) Regine Mugeni et al. Frontiers in Endocrinology
- Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
- (2019) Vjera Ninčević et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- SGLT2 inhibitors and urinary tract infections
- (2019) John Wilding Nature Reviews Endocrinology
- Molecular imaging of β-cells: diabetes and beyond
- (2018) Weijun Wei et al. ADVANCED DRUG DELIVERY REVIEWS
- Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials
- (2018) D. Li et al. DIABETES & METABOLISM
- Development of SGLT1 and SGLT2 inhibitors
- (2018) Timo Rieg et al. DIABETOLOGIA
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
- (2018) Motoaki Sano Journal of Cardiology
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
- (2017) Tsung-Ming Lee et al. FREE RADICAL BIOLOGY AND MEDICINE
- Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease
- (2017) Vaibhav B. Patel et al. HEART FAILURE REVIEWS
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors: are they safe?
- (2017) Sebastian Filippas-Ntekouan et al. POSTGRADUATE MEDICINE
- Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis
- (2017) William L. Baker et al. Journal of the American Heart Association
- Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
- (2017) Mohsen Mazidi et al. Journal of the American Heart Association
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
- (2016) Muhammad Abdul-Ghani et al. DIABETES CARE
- The effect of dapagliflozin on renal function in patients with type 2 diabetes
- (2016) Donald Elliott Kohan et al. JOURNAL OF NEPHROLOGY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β -cell function and reduction of insulin resistance
- (2016) Hideaki Kaneto et al. Journal of Diabetes
- Renal effects of canagliflozin in type 2 diabetes mellitus
- (2015) Vlado Perkovic et al. CURRENT MEDICAL RESEARCH AND OPINION
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- SGLT2 inhibitor dapagliflozin promotes glucagon secretion in α islet cells
- (2015) Jennifer Sargent Nature Reviews Endocrinology
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin
- (2014) Sandra De Jonghe et al. CHEMICO-BIOLOGICAL INTERACTIONS
- A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
- (2014) Chang Hee Jung et al. Diabetes & Metabolism Journal
- Glucose transport families SLC5 and SLC50
- (2013) Ernest M. Wright MOLECULAR ASPECTS OF MEDICINE
- Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of chronic complications of type 2 diabetes mellitus in outpatients - a cross-sectional hospital based survey in urban China
- (2010) Zhaolan Liu et al. Health and Quality of Life Outcomes
- Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion
- (2008) J. Calado et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More